Trials6 min read
Retatrutide Cuts Knee OA Pain 73%, Sleep Apnea 61%
TRIUMPH-1's ADA 2026 baskets show retatrutide cut WOMAC knee pain 73% and sleep apnea events 61% — beyond weight loss. What it means for buyers.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Industry4 min read
GLP-1s Cut 30 lbs in Menopause: ADA Data
New ATTAIN post-hoc data: women lost up to 30.4 lbs at every menopause stage on an oral GLP-1. What it means and where buyers source GLP-1 peptides.
Trials5 min read
Retatrutide TRANSCEND-T2D-1: 16% Loss in Diabetes
Retatrutide's first Phase 3 diabetes trial hit 1.9% A1C drops and 15.3% weight loss at 40 weeks — published in The Lancet. What it means for buyers.
Industry6 min read
Petrelintide: 10.7% Weight Loss, Placebo-Like GI
Roche's amylin drug petrelintide hit 10.7% weight loss at ADA 2026 with placebo-like GI tolerability. What the ZUPREME-1 data means for buyers.
Industry4 min read
Zenagamtide (Amycretin): 14.6% Loss at ADA 2026
Novo's single-molecule GLP-1/amylin agonist hit 14.6% weight loss and 1.71% A1C drop in Phase 2. What zenagamtide (amycretin) means for buyers.
Industry4 min read
Elecoglipron: AstraZeneca's Oral GLP-1 at ADA 2026
AstraZeneca's oral GLP-1 elecoglipron hit Phase 2b endpoints in VISTA and SOLSTICE. Full weight-loss data drops at ADA June 8. What it means for buyers.
Industry6 min read
CagriSema Diabetes Data Debuts at ADA 2026
Novo's amylin/GLP-1 combo unveils first REIMAGINE diabetes results June 7 — 14.2% weight loss, 1.91% A1C drop. What it means for buyers.
Industry6 min read
Pep19: Peptide Cuts Visceral Fat 17%, No GLP-1
Pep19 cut visceral fat 17% and improved sleep in a 60-day trial — without GLP-1. A CB1 inverse-agonist peptide now sold as Nutroslim. What the data shows.
Industry7 min read
Do GH Peptides Desensitize the Pituitary?
Community protocols cycle 8 weeks on, 8 off to avoid desensitization. The trial data tells a more nuanced story — by peptide and by receptor.
Industry5 min read
Why GLP-1 Weight Loss Stalls: NIH Finds the Mechanism
NIH Nature Metabolism study: semaglutide plateaus happen because hindbrain neurons shut down cAMP signaling. PDE4 inhibitors may break it.
Industry4 min read
VC-Funded Peptide Startups Race to Build Before FDA Rules
Venture-backed startups raised $22M+ betting on peptide legalization this summer. Who they are, what they sell, and what it means for buyers.
Industry5 min read
GLP-1s Cut Cancer Metastasis Risk Up to 50%: ASCO Data
ASCO 2026 data: semaglutide and liraglutide users had 36-50% lower metastasis rates across lung, breast, colorectal, and liver cancers. The buyer breakdown.
Industry8 min read
What Is Bacteriostatic Water? Uses, Safety & Storage
One ingredient separates bacteriostatic water from sterile water — and that ingredient is the entire reason multi-dose peptide vials work.
Regulatory5 min read
GLP-1s Now FDA-Approved for Fatty Liver Disease
Semaglutide and tirzepatide both FDA-approved for MASH. 63% resolution rate, fibrosis reversal in trials. What the data shows and sourcing options.
Industry7 min read
Can You Make Bacteriostatic Water at Home? Risks
The DIY recipe is simple. The risks aren't. Why homemade bac water fails sterility, concentration, and pyrogen tests that take 30 seconds to buy around.
Industry5 min read
Teens Injecting Peptides: The Looksmaxxing Safety Crisis
Teen peptide injection rates are surging via looksmaxxing culture. Contamination data, organ-damage risks, and what COA-verified sourcing actually looks like.
Industry6 min read
GLP-1s Cut Heart Attack Risk 13% Across 91,490 Patients
Largest GLP-1 cardiovascular meta-analysis yet — 11 RCTs, 91,490 patients, 2.7-year follow-up. Semaglutide and liraglutide lead. What it means for you.
Trials6 min read
Retatrutide Hits 30.3% Weight Loss in TRIUMPH-1
TRIUMPH-1 Phase 3 data drops: 30.3% body weight loss at 104 weeks, 2,339 patients. What the numbers mean for the NDA and buyers.